Clinical pharmacokinetics of leriglitazone and a translational approach using PBPK modeling to guide the selection of the starting dose in children

• Hlavní autoři: Estefania Traver (Autor), Laura Rodríguez‐Pascau (Autor), Uwe Meya (Autor), Guillem Pina (Autor), Silvia Pascual (Autor), Sonia Poli (Autor), David Eckland (Autor), Jeroen van deWetering (Autor), Alice Ke (Autor), Andreas Lindauer (Autor), Marc Martinell (Autor), Pilar Pizcueta (Autor)
• Médium: Kniha
• Vydáno: Wiley, 2024-06-01T00:00:00Z.
• Témata: article
• On-line přístup: Connect to this object online.

Abstract Leriglitazone is a unique peroxisome proliferator‐activated receptor‐gamma (PPARγ) agonist that crosses the blood-brain barrier in humans and clinical trials have shown evidence of efficacy in neurodegenerative diseases. At clinical doses which are well‐tolerated, leriglitazone reaches the...